Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held from May 30 to June 3, 2025, at the McCormick Place in Chicago, IL.
The poster presentation will detail development progress for EGL-001, a novel therapeutic agent with first-in-class potential. EGL-001 is designed to provide checkpoint inhibition by antagonizing the CTLA-4-CD80/86 interaction while selectively depleting intratumoral Tregs by downregulating CD25 and inhibiting IL-2 signaling specifically within these cells. EGL-001 is currently being assessed in the EGL-121 clinical trial (NCT06622486), a Phase I/II, multicenter, open-label study evaluating the safety, tolerability, and initial activity of EGL-001 in adult patients with selected advanced and/or metastatic solid tumors who have initially benefited (secondary resistance) from an ICI treatment as monotherapy or in combination as SoC.
Details of the poster presentation are as follows:
· Poster Board Number: 317a
· Poster Title: EGL-121, a first-in-human phase 1/2 trial of EGL-001 in adult patients with selected advanced and/or metastatic solid tumors.
· Session Title: Developmental Therapeutics – Immunotherapy
· Session Date and Time: Monday, June 2, 2025, 1:30 p.m. – 4:30 p.m. CDT
· Location: Hall A – Posters and Exhibits
Additional information, including the accepted abstract, can be accessed on the 2025 ASCO Annual Meeting website. Presentation materials will be made available on the company’s website following the event.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells (Tregs). Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, Egle has completed regulatory studies and manufacturing for EGL-003 to enable a CTA filing and is preparing to launch a clinical trial in 2025. Find out more at www.egle-tx.com.
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57